Significance of proteomic fingerprints on shifting the NSCLC patients with Gefltinib / 肿瘤研究与临床

ABSTRACT

Objective Verification of the serum proteomic fingerprints of NSCLC (non-small cell lung cancer) patients related to their advantage in Gefitinib therapy. Methods 27 NSCLC patients who have been treated with Gefitinib for more than 1 month and attained certain efficacy were taken for examination. They were divided into 3 groups, CR+PR, SD and PD, according to the evaluation criteria of solid tumor curative efficacy. All patients received SELDI (SELDI-TOF-MS surface-enhanced laser desorption/ionization time-of-flight mass spectrometry technique) inspection before treatment with Gefitinib. The shifting procedure was based on the abundance of the fingerprint"M/Z 8693 50H+". According to the abundance of this fingerprint founded, the patients were divided into 4 populations 1. The advantage population (10 patients, abundance 10 %);2. The disadvantage population (7 patients, abundance≥30 %);3. Suspected population A (5 patients, abundance 11%-15 %);4. Suspected population B (5 patients, abundance 16～ 29%). The ratio of patients in each of the 3 groups (CR + PR, SD and PD) into each of the above 4 populations were analyzed. Results It showed that 1. In the advantage population, the ratio dispersed from CR + PR group is 9/10, those from SD group is 1/10 and from PD is 0.2. In the disadvantage population, the ratio dispersed from CR + PR group is 1/7, those from SD group is 1/7 and from PD is 5/7. In the suspected A group, the ratio from CR + PR group is 3/5, those from SD group is 1/5 and from PD is 1/5. 4. In the suspected B group, the ratio from CR + PR group is 3/5, those from SD group is 1/5 and from PD is 1/5. Conclusion This fingerprint "M/Z 8693 50H+" with abundance 10% after SELDI inspection is the index choosing advantage patients suitable to receive Gefitinib therapy.